ClinicalTrials.Veeva

Menu

Postoperative Pain Control & Relief in Neonates (POPCORN)

S

Saint Louis University (SLU)

Status and phase

Terminated
Phase 4

Conditions

Pain, Postoperative
Opioid Use
Premature Infant

Treatments

Drug: Acetaminophen
Drug: Saline

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

Pain control for newborns has made significant improvements over the last 30 years. The use of narcotics remains the standard of care for neonates undergoing minor and major surgeries. Narcotics, however, are associated with adverse effects such as respiratory depression, prolonged intubation and withdrawal symptoms. Acetaminophen (Tylenol©) has been proposed as an adjunct to reduce narcotic use but current evidence from well designed studies in newborns and premature infants is limited. This study will randomly assign neonates undergoing a surgery to either morphine plus acetaminophen or morphine alone for pain control. The subjects will be followed for 72 hours after the operation and evaluate the benefits of acetaminophen for pain control.

Enrollment

11 patients

Sex

All

Ages

Under 1 month old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • All neonates ≥ 28 weeks of gestation and <44 weeks of gestation undergoing general surgery procedures (below) and managed postoperatively in the Neonatal Intensive Care Unit (NICU).

Minor procedures Inguinal hernia repair Laparoscopic or open gastrostomy tube placement Peritoneal drain placement for spontaneous intestinal perforation Gastroschisis bedside patch closure

Major procedures Laparoscopic or open Nissen fundoplication, duodenal atresia repair, Hirschsprung pull through, Ladd's procedure or excision of abdominal cyst Thoracoscopy or thoracotomy procedure Enterostomy or colostomy creation Exploratory laparotomy Revision or closure of enterostomy or colostomy Any Gastroschisis or omphalocele repair in operating room Repair or staged repair of congenital anorectal malformations Resection of sacrococcygeal teratoma

Exclusion criteria

  • Any infant admitted with preoperative diagnosis of neonatal abstinence syndrome (NAS) or known intrauterine opiate exposure
  • Any diagnosis of hepatitis exclusive of TPN-related biliary cholestasis
  • Renal disease with creatinine >2.0 mg/dl at enrollment
  • Intraventricular hemorrhage grade 3 or greater, or cerebellar hemorrhage
  • Any patient with myotonic dystrophy or other congenital disease limiting validity of pain scoring
  • Opiate exposure within 14 days of operative procedure
  • Non-English-speaking parents/guardians

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

11 participants in 2 patient groups, including a placebo group

Intravenous Acetaminophen
Active Comparator group
Description:
Infants randomized to the intervention arm will receive scheduled IV acetaminophen per LexiComp dosing guideline (28 0/7-32 6/7 weeks 10 mg/kg/dose every 12 hours; 33 0/7-38 6/7 weeks 10 mg/kg/dose every 8 hours; \>39 0/7 weeks 10 mg/kg/dose every 6 hours). N-PASS scores will guide administration of IV morphine. Continuous infusion of morphine will be started if an infant requires 3 doses of morphine within a 6-hour period and titrated as needed per N-PASS scores.
Treatment:
Drug: Acetaminophen
Intravenous Placebo
Placebo Comparator group
Description:
Infants randomized to the control arm will receive normal saline placebo IV at the appropriate volume and times for the gestational age. IV acetaminophen is concentrated at 10 mg/ml; corresponding saline volumes will be 1 ml to 5 ml, approximately, based on subject weight. Control infants will also have N-PASS scores assessed using the same protocol following the surgical procedure for 72 hours. Dosing of IV morphine will be the same as the dosing for the intervention arm.
Treatment:
Drug: Saline

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems